Selecting Patients for Hyperthermia Treatment Based on Patient Backgrounds
Use of hyperthermia as cancer treatment has often been impossible to continue at once following exacerbation of general condition due to cancer growth. However, no formal consensus has yet been defined regarding the acceptability of hyperthermia, so selection of patients for hyperthermia is not base...
Saved in:
| Published in | Thermal Medicine Vol. 27; no. 2; pp. 51 - 60 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English Japanese |
| Published |
Japanese Society for Thermal Medicine
20.06.2011
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1882-2576 1882-3750 |
| DOI | 10.3191/thermalmed.27.51 |
Cover
| Abstract | Use of hyperthermia as cancer treatment has often been impossible to continue at once following exacerbation of general condition due to cancer growth. However, no formal consensus has yet been defined regarding the acceptability of hyperthermia, so selection of patients for hyperthermia is not based on agreed clinical criteria. Aiming at the establishment of agreed clinical criteria concerning the selection of patients for hyperthermia, this report examined the treatment acceptability of hyperthermia based on patient backgrounds before advanced cancer treatment. Subjects comprised 45 patients with various advanced cancers treated with regional hyperthermia combined with chemo- or immunotherapy who visited our clinic between July 2008 and May 2009. Group A (n=24) underwent hyperthermia ≥ 8 times, while Group B (n=21) underwent hyperthermia ≤ 7 times (mean, 4.19 times). We investigated pretreatment laboratory data, body mass index, performance status (PS), Glasgow prognostic score (GPS), and quality of life (QOL). Patients with poor scores for both PS and GPS dropped out early. In these patients, elevations in both lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels tended to be present in addition to hypoalbuminemia. QOL in Group B was already impaired before initiation of hyperthermia. PS and GPS appear to represent the most important factors when judging the acceptability of hyperthermia, while LDH, CRP, and albumin levels may help such judgments. The acceptability of hyperthermia can be predicted using patient background as evidenced by laboratory data and general conditions, including QOL, before cancer treatment. The results justified further examination in a large number of patients to aim the establishment of agreed clinical criteria concerning the selection of patients for hyperthermia. |
|---|---|
| AbstractList | Use of hyperthermia as cancer treatment has often been impossible to continue at once following exacerbation of general condition due to cancer growth. However, no formal consensus has yet been defined regarding the acceptability of hyperthermia, so selection of patients for hyperthermia is not based on agreed clinical criteria. Aiming at the establishment of agreed clinical criteria concerning the selection of patients for hyperthermia, this report examined the treatment acceptability of hyperthermia based on patient backgrounds before advanced cancer treatment. Subjects comprised 45 patients with various advanced cancers treated with regional hyperthermia combined with chemo- or immunotherapy who visited our clinic between July 2008 and May 2009. Group A (n=24) underwent hyperthermia > 8 times, while Group B (n=21) underwent hyperthermia < 7 times (mean, 4.19 times). We investigated pretreatment laboratory data, body mass index, performance status (PS), Glasgow prognostic score (GPS), and quality of life (QOL). Patients with poor scores for both PS and GPS dropped out early. In these patients, elevations in both lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels tended to be present in addition to hypoalbuminemia. QOL in Group B was already impaired before initiation of hyperthermia. PS and GPS appear to represent the most important factors when judging the acceptability of hyperthermia, while LDH, CRP, and albumin levels may help such judgments. The acceptability of hyperthermia can be predicted using patient background as evidenced by laboratory data and general conditions, including QOL, before cancer treatment. The results justified further examination in a large number of patients to aim the establishment of agreed clinical criteria concerning the selection of patients for hyperthermia. Use of hyperthermia as cancer treatment has often been impossible to continue at once following exacerbation of general condition due to cancer growth. However, no formal consensus has yet been defined regarding the acceptability of hyperthermia, so selection of patients for hyperthermia is not based on agreed clinical criteria. Aiming at the establishment of agreed clinical criteria concerning the selection of patients for hyperthermia, this report examined the treatment acceptability of hyperthermia based on patient backgrounds before advanced cancer treatment. Subjects comprised 45 patients with various advanced cancers treated with regional hyperthermia combined with chemo- or immunotherapy who visited our clinic between July 2008 and May 2009. Group A (n=24) underwent hyperthermia ≥ 8 times, while Group B (n=21) underwent hyperthermia ≤ 7 times (mean, 4.19 times). We investigated pretreatment laboratory data, body mass index, performance status (PS), Glasgow prognostic score (GPS), and quality of life (QOL). Patients with poor scores for both PS and GPS dropped out early. In these patients, elevations in both lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels tended to be present in addition to hypoalbuminemia. QOL in Group B was already impaired before initiation of hyperthermia. PS and GPS appear to represent the most important factors when judging the acceptability of hyperthermia, while LDH, CRP, and albumin levels may help such judgments. The acceptability of hyperthermia can be predicted using patient background as evidenced by laboratory data and general conditions, including QOL, before cancer treatment. The results justified further examination in a large number of patients to aim the establishment of agreed clinical criteria concerning the selection of patients for hyperthermia. |
| Author | NAITO, YUJI SAKAMOTO, NAOYUKI ISHIKAWA, TAKESHI TANIGAWA, MARI YOSHIKAWA, TOSHIKAZU KOKURA, SATOSHI |
| Author_xml | – sequence: 1 fullname: NAITO, YUJI organization: Molecular Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine – sequence: 1 fullname: SAKAMOTO, NAOYUKI organization: Hyakumanben Clinic – sequence: 1 fullname: ISHIKAWA, TAKESHI organization: Molecular Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine – sequence: 1 fullname: TANIGAWA, MARI organization: Hyakumanben Clinic – sequence: 1 fullname: YOSHIKAWA, TOSHIKAZU organization: Molecular Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine – sequence: 1 fullname: KOKURA, SATOSHI organization: Molecular Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine |
| BookMark | eNpdUF1PwjAUbQwmAvru4_7AsB9b2z0qQdGQaCI-N113C8OtI-144N9bBCTx4X7fc87NHaGB6xwgdE_whJGCPPRr8K1uWqgmVExycoWGREqaMpHjwSmnueA3aBTCBmNOBM6G6O0TGjB97VbJh-5rcH1IbOeT-X4L_pez1snSg-7bOEuedIAq6dx5OTbM98p3O1eFW3RtdRPg7hTH6Ot5tpzO08X7y-v0cZGaqE9SaaTAprJgtADNRGaElFIUWOdScmtNUTJWlpk1llnLmWYlpQUFw0GKjBZsjPCR1_guBA9WbX3dar9XBKvDL9TlF4oKlZMImR0hsVUb3XSuqR2oTbfzLp6qjMv6dYQoiglRGFOBaQwsWn6oOSEF4_zCswm9XsGfsPZ9bRr4J0yPLjKc52atvQLHfgDZPYek |
| Cites_doi | 10.3109/02656736.2010.500645 10.1016/j.ejca.2008.10.026 |
| ContentType | Journal Article |
| Copyright | 2011 Japanese Society for Thermal Medicine |
| Copyright_xml | – notice: 2011 Japanese Society for Thermal Medicine |
| CorporateAuthor | Hyakumanben Clinic Graduate School of Medical Sciences Molecular Gastroenterology and Hepatology Kyoto Prefectural University of Medicine |
| CorporateAuthor_xml | – name: Hyakumanben Clinic – name: Molecular Gastroenterology and Hepatology – name: Kyoto Prefectural University of Medicine – name: Graduate School of Medical Sciences |
| DBID | AAYXX CITATION |
| DOI | 10.3191/thermalmed.27.51 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1882-3750 |
| EndPage | 60 |
| ExternalDocumentID | 10_3191_thermalmed_27_51 cn4thrma_2011_002702_003_0051_006119366 article_thermalmed_27_2_27_2_51_article_char_en |
| GroupedDBID | 123 29Q 2WC 53G ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK E3Z JMI JSF JSH KQ8 MOJWN OK1 RJT RNS RZJ TR2 TKC AAYXX CITATION |
| ID | FETCH-LOGICAL-c2571-8c870cdfeca7ea374c7888790a5886ffc9b33bb4fcf3ff63a3b2292ec6e874293 |
| ISSN | 1882-2576 |
| IngestDate | Tue Jul 01 01:04:22 EDT 2025 Tue Apr 08 16:20:18 EDT 2025 Wed Sep 03 06:29:12 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 2 |
| Language | English Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c2571-8c870cdfeca7ea374c7888790a5886ffc9b33bb4fcf3ff63a3b2292ec6e874293 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/thermalmed/27/2/27_2_51/_article/-char/en |
| PageCount | 10 |
| ParticipantIDs | crossref_primary_10_3191_thermalmed_27_51 medicalonline_journals_cn4thrma_2011_002702_003_0051_006119366 jstage_primary_article_thermalmed_27_2_27_2_51_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011/06/20 |
| PublicationDateYYYYMMDD | 2011-06-20 |
| PublicationDate_xml | – month: 06 year: 2011 text: 2011/06/20 day: 20 |
| PublicationDecade | 2010 |
| PublicationTitle | Thermal Medicine |
| PublicationTitleAlternate | Thermal Med. |
| PublicationYear | 2011 |
| Publisher | Japanese Society for Thermal Medicine |
| Publisher_xml | – name: Japanese Society for Thermal Medicine |
| References | 1) Huilgol N.G., Gupta S., Dixit R. : Chemoradiation with hyperthermia in the treatment of head and neck cancer. Int J Hyperthermia, 26 : 21-25, 2010. 12) Koch A., Fohlin H., Sörenson S. : Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol, 4 : 326-332, 2009. 3) Fotopoulou C., Hee Cho C., Kraetschell R., Gellermann J., Wust P., Lichtenegger W., Sehouli J. : Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse : Results of a pilot study. Int J Hyperthermia, 26 : 118-126, 2010. 8) Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B., de Haes J.C., Kaasa S., Klee M., Osoba D., Razavi D., Rofe P.B., Schraub S., Sneeuw K., Sullivan M., Takeda F. : The European Organization for Research and Treatment of Cancer QLQ-C30 : A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 85 : 365-376, 1993. 9) Homs M.Y., Essink-Bot M.L., Borsboom G.J., Steyerberg E.W., Siersema P.D., Dutch SIREC Study Group : Quality of life after palliative treatment for oesophageal carcinoma - a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer, 40 : 1862-1871, 2004. 5) Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. : New response evaluation criteria in solid tumours : Revised RECIST guideline (version 1.1). Eur J Cancer, 45 : 228-247, 2009. 7) Forrest L.M., McMillan D.C., McArdle C.S., Angerson W.J., Dunlop D.J. : Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer, 90 : 1704-1706, 2004. 2) Oldenborg S., Van Os R.M., Van rij C.M., Crezee J., Van de Kamer J.B., Rutgers E.J., Geijsen E.D., Zum vörde sive vörding P.J., Koning C.C., Van tienhoven G. : Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer : A retrospective study. Int J Hyperthermia, 26 : 136-144, 2010. 6) Forrest L.M., McMillan D.C., McArdle C.S., Angerson W.J., Dunlop D.J. : Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer, 89 : 1028-1030, 2003. 15) Shen H., Li X.D., Wu C.P., Yin Y.M., Wang R.S., Shu Y.Q. : The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer : A phase II study. Int J Hyperthermia, 27 : 27-32, 2011. 16) Jiang Z., Yan W., Ming J., Yu Y. : Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer : A preliminary study. BMC Cancer, 7 : 189, 2007. 13) Brown D.J., Milroy R., Preston T., McMillan D.C. : The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol, 60 : 705-708, 2007. 4) Ishikawa T., Kokura S., Inui T., Suzuki K., Matsuyama R., Okita M., Isozaki Y., Nagao Y., Ando T., Naito Y., Yoshida N., Yoshikawa T. : Effects of sequential combination of hyperthermia and gemcitabine in the treatment of advanced unresectable pancreatic cancer : A retrospective study. Thermal Med, 24 : 131-139, 2008. 11) Morita T., Chinone Y., Ikenaga M., Miyoshi M., Nakaho T., Nishitateno K., Sakonji M., Shima Y., Suenaga K., Takigawa C., Kohara H., Tani K., Kawamura Y., Matsubara T., Watanabe A., Yagi Y., Sasaki T., Higuchi A., Kimura H., Abo H., Ozawa T., Kizawa Y., Uchitomi Y. : Japan Pain, Palliative Medicine, Rehabilitation, and Psycho-Oncology Study Group. Ethical validity of palliative sedation therapy : A multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage, 30 : 308-319, 2005. 14) Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E. : Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest, 24 : 576-580, 2006. 10) Schulte T., Schniewind B., Walter J., Dohrmann P., Küchler T., Kurdow R. : Age-related impairment of quality of life after lung resection for non-small cell lung cancer. Lung Cancer, 68 : 115-120, 2010. 11 12 13 14 15 16 1 2 3 4 5 6 7 8 9 10 |
| References_xml | – reference: 6) Forrest L.M., McMillan D.C., McArdle C.S., Angerson W.J., Dunlop D.J. : Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer, 89 : 1028-1030, 2003. – reference: 16) Jiang Z., Yan W., Ming J., Yu Y. : Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer : A preliminary study. BMC Cancer, 7 : 189, 2007. – reference: 1) Huilgol N.G., Gupta S., Dixit R. : Chemoradiation with hyperthermia in the treatment of head and neck cancer. Int J Hyperthermia, 26 : 21-25, 2010. – reference: 7) Forrest L.M., McMillan D.C., McArdle C.S., Angerson W.J., Dunlop D.J. : Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer, 90 : 1704-1706, 2004. – reference: 10) Schulte T., Schniewind B., Walter J., Dohrmann P., Küchler T., Kurdow R. : Age-related impairment of quality of life after lung resection for non-small cell lung cancer. Lung Cancer, 68 : 115-120, 2010. – reference: 14) Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E. : Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest, 24 : 576-580, 2006. – reference: 3) Fotopoulou C., Hee Cho C., Kraetschell R., Gellermann J., Wust P., Lichtenegger W., Sehouli J. : Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse : Results of a pilot study. Int J Hyperthermia, 26 : 118-126, 2010. – reference: 12) Koch A., Fohlin H., Sörenson S. : Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol, 4 : 326-332, 2009. – reference: 4) Ishikawa T., Kokura S., Inui T., Suzuki K., Matsuyama R., Okita M., Isozaki Y., Nagao Y., Ando T., Naito Y., Yoshida N., Yoshikawa T. : Effects of sequential combination of hyperthermia and gemcitabine in the treatment of advanced unresectable pancreatic cancer : A retrospective study. Thermal Med, 24 : 131-139, 2008. – reference: 8) Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B., de Haes J.C., Kaasa S., Klee M., Osoba D., Razavi D., Rofe P.B., Schraub S., Sneeuw K., Sullivan M., Takeda F. : The European Organization for Research and Treatment of Cancer QLQ-C30 : A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 85 : 365-376, 1993. – reference: 13) Brown D.J., Milroy R., Preston T., McMillan D.C. : The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol, 60 : 705-708, 2007. – reference: 11) Morita T., Chinone Y., Ikenaga M., Miyoshi M., Nakaho T., Nishitateno K., Sakonji M., Shima Y., Suenaga K., Takigawa C., Kohara H., Tani K., Kawamura Y., Matsubara T., Watanabe A., Yagi Y., Sasaki T., Higuchi A., Kimura H., Abo H., Ozawa T., Kizawa Y., Uchitomi Y. : Japan Pain, Palliative Medicine, Rehabilitation, and Psycho-Oncology Study Group. Ethical validity of palliative sedation therapy : A multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage, 30 : 308-319, 2005. – reference: 5) Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. : New response evaluation criteria in solid tumours : Revised RECIST guideline (version 1.1). Eur J Cancer, 45 : 228-247, 2009. – reference: 9) Homs M.Y., Essink-Bot M.L., Borsboom G.J., Steyerberg E.W., Siersema P.D., Dutch SIREC Study Group : Quality of life after palliative treatment for oesophageal carcinoma - a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer, 40 : 1862-1871, 2004. – reference: 15) Shen H., Li X.D., Wu C.P., Yin Y.M., Wang R.S., Shu Y.Q. : The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer : A phase II study. Int J Hyperthermia, 27 : 27-32, 2011. – reference: 2) Oldenborg S., Van Os R.M., Van rij C.M., Crezee J., Van de Kamer J.B., Rutgers E.J., Geijsen E.D., Zum vörde sive vörding P.J., Koning C.C., Van tienhoven G. : Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer : A retrospective study. Int J Hyperthermia, 26 : 136-144, 2010. – ident: 2 – ident: 3 – ident: 4 – ident: 15 doi: 10.3109/02656736.2010.500645 – ident: 5 doi: 10.1016/j.ejca.2008.10.026 – ident: 1 – ident: 12 – ident: 11 – ident: 10 – ident: 13 – ident: 16 – ident: 14 – ident: 6 – ident: 9 – ident: 7 – ident: 8 |
| SSID | ssj0061704 |
| Score | 1.7665803 |
| Snippet | Use of hyperthermia as cancer treatment has often been impossible to continue at once following exacerbation of general condition due to cancer growth.... |
| SourceID | crossref medicalonline jstage |
| SourceType | Index Database Publisher |
| StartPage | 51 |
| SubjectTerms | acceptability Glasgow prognostic score (GPS) hyperthermia performance status (PS) quality of life (QOL) |
| Title | Selecting Patients for Hyperthermia Treatment Based on Patient Backgrounds |
| URI | https://www.jstage.jst.go.jp/article/thermalmed/27/2/27_2_51/_article/-char/en http://mol.medicalonline.jp/en/journal/download?GoodsID=cn4thrma/2011/002702/003&name=0051-0061u |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Thermal Medicine, 2011/06/20, Vol.27(2), pp.51-60 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfKQAgJIb4mxpfywAuKUlIncdoXJIMG7aI2sKZiPFm2EwuG1qERXnjgb-cujtO02sOAF6tyHTu5O59_5_OdCXlRaQMo3oSBMZUKYkVZIGWiAMixGCwQLZnB2OH5gk1X8dFJcjIY_O5Hl9RqqH9dGlfyL1yFOuArRsn-BWe7TqECfgN_oQQOQ3klHi-bS2zQ2P9g06M2yRX8KdiWFwjszr5Kv-hOkr-BBatE50DbGCr0N4zqaIN9HUYt8Mk2ZLfvdl_w_PMqm_lLnvF5XuTd5gwv8uV05md5tjruBKLg2SHW4oZYxj919XN-PPMLvpi9d5XlZhOVBTTcrAewjuP9mFsnSy99OatUEcWjYdPXujYjQCtdtKdC2_yzdjG2idp31TyoDVTztR0RUMOQpkP33FbybL2O6y_QSOBXCLTBQ4rpUAUqI4H4DQAsY9fIdZqmjZs_-9h5oTBXfXMqwb2_dXPj6K92x96CNTdOAdljyobbZ9bbZrOe9IBLcZfcaS0Oj1vxuUcGp_I-ueno94AcdVLkOSnygNJeX4q8Toq8Roq887Vr7PWk6CFZvTss3k6D9oaNQMP3jIKxBnWtS1NpmVYySmONOyLpJJTJeMyM0RMVRUrFRpvIGBbJSFE6oZVm1TgFJBPtk731-bp6RLxSpQmgXUCLAFDVRKmS0nJUSl1C2yhUB-SlI5D4bhOpCDBAkZhiQ0xBU5GMDshrS8GuZTvFdlpSWwAn3f8YqgiaATrYorxoJ-0PcUWBePy_HTwhtzYT5ynZqy9-Vs8AvtbqeSNjfwA_rJyd |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Selecting+Patients+for+Hyperthermia+Treatment+Based+on+Patient+Backgrounds&rft.jtitle=Thermal+Medicine&rft.au=NAOYUKI+SAKAMOTO&rft.au=SATOSHI+KOKURA&rft.au=TAKESHI+ISHIKAWA&rft.au=MARI+TANIGAWA&rft.date=2011-06-20&rft.pub=Japanese+Society+for+Thermal+Medicine&rft.issn=1882-2576&rft.volume=27&rft.issue=2&rft.spage=51&rft.epage=61&rft_id=info:doi/10.3191%2Fthermalmed.27.51&rft.externalDocID=cn4thrma_2011_002702_003_0051_006119366 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1882-2576&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1882-2576&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1882-2576&client=summon |